A Study Comparing an Intracanalicular Dexamethasone Insert to Traditional Eye Drops for Managing Pain and Inflammation After Sequential Bilateral Cataract Surgery

What this Trial Is About

This research investigates patient preference and the safety and eye-related effectiveness of a new treatment method called Dextenza combined with an intracameral antibiotic and NSAID, compared to standard eye drop therapy after cataract surgery. The study involves patients undergoing surgery in both eyes and aims to control pain and inflammation following the procedures. Participants will be randomly assigned to receive either the experimental treatment or the standard topical therapy in their first eye surgery. The experimental group receives a Dextenza dexamethasone intracanalicular insert placed in the lower punctum during surgery, along with intracameral ketorolac and moxifloxacin administered during and after the procedure. The control group receives standard topical drops including moxifloxacin, ketorolac, and prednisolone acetate at scheduled intervals before and after surgery. Two weeks later, the second eye will be operated on and treated with the alternate treatment. During the study, participants will attend several visits for assessments including patient preference measured 28 days after the second eye surgery, ocular inflammation scores, post-operative pain ratings, visual acuity tests, physician evaluations of insertion, and monitoring for adverse events. These evaluations occur at various time points up to two months following the second surgery, enabling researchers to compare the treatments comprehensively and monitor safety and effectiveness over time.

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery